rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2000-7-6
|
pubmed:abstractText |
Nonselective cyclooxygenase (COX) inhibitors are potent tocolytic agents; however, they also have adverse fetal effects such as constriction of the fetal ductus arteriosus. Recently, selective COX-2 inhibitors have been used in the management of preterm labor in the hope of avoiding fetal complications. However, both COX-1 and -2 are expressed by cells of the ductus arteriosus. We used fetal lambs (0.88 gestation) to assess the ability of selective COX-2 inhibitors celecoxib and NS398 to affect the ductus arteriosus. Both selective COX-2 inhibitors decreased PGE(2) and 6ketoPGF(1alpha) production in vitro; both inhibitors constricted the isolated ductus in vitro. The nonselective COX-1/COX-2 inhibitor indomethacin produced a further reduction in PG release and an additional increase in ductus tension in vitro. We used a prodrug of celecoxib to achieve 1.4 +/- 0.6 microg/ml, mean +/- standard deviation, of the active drug in vivo. This concentration of celecoxib produced both an increase in pressure gradient and resistance across the ductus; celecoxib also decreased fetal plasma concentrations of PGE(2) and 6ketoPGF(1alpha). Indomethacin (0.7 +/- 0.2 microg/ml) produced a significantly greater fall in ductus blood flow than celecoxib and tended to have a greater effect on ductus resistence in vivo. We conclude that caution should be used when recommending COX-2 inhibitors for use in pregnant women, because COX-2 appears to play a significant role in maintaining patency of the fetal ductus arteriosus.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-Ketoprostaglandin F1 alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone,
http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol,
http://linkedlifedata.com/resource/pubmed/chemical/Indomethacin,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/N-(2-cyclohexyloxy-4-nitrophenyl)met...,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrobenzenes,
http://linkedlifedata.com/resource/pubmed/chemical/Nitroprusside,
http://linkedlifedata.com/resource/pubmed/chemical/Oxygen,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Vasodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/celecoxib
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0363-6119
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
278
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
R1496-505
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10848516-6-Ketoprostaglandin F1 alpha,
pubmed-meshheading:10848516-Animals,
pubmed-meshheading:10848516-Cyclooxygenase 1,
pubmed-meshheading:10848516-Cyclooxygenase 2,
pubmed-meshheading:10848516-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:10848516-Cyclooxygenase Inhibitors,
pubmed-meshheading:10848516-Dinoprostone,
pubmed-meshheading:10848516-Ductus Arteriosus,
pubmed-meshheading:10848516-Epoprostenol,
pubmed-meshheading:10848516-Female,
pubmed-meshheading:10848516-Hemodynamics,
pubmed-meshheading:10848516-Indomethacin,
pubmed-meshheading:10848516-Isoenzymes,
pubmed-meshheading:10848516-Nitrobenzenes,
pubmed-meshheading:10848516-Nitroprusside,
pubmed-meshheading:10848516-Oxygen,
pubmed-meshheading:10848516-Pregnancy,
pubmed-meshheading:10848516-Prostaglandin-Endoperoxide Synthases,
pubmed-meshheading:10848516-Pulmonary Artery,
pubmed-meshheading:10848516-Pyrazoles,
pubmed-meshheading:10848516-Sheep,
pubmed-meshheading:10848516-Sulfonamides,
pubmed-meshheading:10848516-Vasoconstriction,
pubmed-meshheading:10848516-Vasodilator Agents
|
pubmed:year |
2000
|
pubmed:articleTitle |
Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.
|
pubmed:affiliation |
Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 94143-0544, USA.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|